The noradrenergic paradox: implications in the management of depression and anxiety
Alonso Montoya,1 Robert Bruins,1 Martin A Katzman,2 Pierre Blier3 1Eli Lilly Canada Inc, 2START Clinic for the Mood and Anxiety Disorders, Toronto, 3Mood Disorders Research Unit, Institute of Mental Health Research, University of Ottawa, Ottawa, ON, Canada Abstract: Both major depressive disorder...
Guardado en:
Autores principales: | Montoya A, Bruins R, Katzman MA, Blier P |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9701dfa3f71a4f9b986792dc2674e4b7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone
por: McIntyre RS
Publicado: (2017) -
Selective serotonin reuptake inhibitors may lead to improved cataract surgery outcomes in patients with amblyopia
por: Xin KZ, et al.
Publicado: (2019) -
Safety and Efficacy of Centanafadine Sustained-Release in Adults With Attention-Deficit Hyperactivity Disorder: Results of Phase 2 Studies
por: Wigal SB, et al.
Publicado: (2020) -
Noradrenaline plays a critical role in the switch to a manic episode and treatment of a depressive episode
por: Kurita M
Publicado: (2016) -
An observational study of duloxetine versus SSRI monotherapy in Japanese patients with major depressive disorder: subgroup analyses of treatment effectiveness for pain, depressive symptoms, and quality of life
por: Kuga A, et al.
Publicado: (2017)